A5088841645- Monoclonal and Polyclonal Antibodies Research
- Nanoparticle-Based Drug Delivery
- RNA Interference and Gene Delivery
- Advanced Radiotherapy Techniques
- Sarcoma Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Cancer, Hypoxia, and Metabolism
- Cancer Treatment and Pharmacology
- S100 Proteins and Annexins
- melanin and skin pigmentation
- CAR-T cell therapy research
- Radiomics and Machine Learning in Medical Imaging
- RNA regulation and disease
- Cancer Cells and Metastasis
- Cancer Diagnosis and Treatment
- Diet and metabolism studies
- Cancer Research and Treatments
Tel Aviv University
2022
Université Paris-Sud
2018
École Pratique des Hautes Études
2018
Inserm
2018
Université Paris-Saclay
2018
Exercise prevents cancer incidence and recurrence, yet the underlying mechanism behind this relationship remains mostly unknown. Here we report that exercise induces metabolic reprogramming of internal organs increases nutrient demand protects against metastatic colonization by limiting availability to tumor, generating an exercise-induced shield. Proteomic ex vivo capacity analyses murine revealed catabolic processes, glucose uptake, mitochondrial activity, GLUT expression. analysis...
Abstract Innovative strategies for enhancing efficacy and overcoming drug resistance in hematologic cancers, such as using antibody–drug conjugates (ADC), have shifted the paradigm of conventional care by delivering promising outcomes cancer therapies with a significant reduction risk relapse. Transferrin receptor (TfR1), cluster differentiation 71 (CD71), is known to be overexpressed malignant cells considered potent antitumor target. Therefore, we developed an anti-CD71 ADC, INA03,...
<div>Abstract<p>Innovative strategies for enhancing efficacy and overcoming drug resistance in hematologic cancers, such as using antibody–drug conjugates (ADC), have shifted the paradigm of conventional care by delivering promising outcomes cancer therapies with a significant reduction risk relapse. Transferrin receptor (TfR1), cluster differentiation 71 (CD71), is known to be overexpressed malignant cells considered potent antitumor target. Therefore, we developed an anti-CD71...
<p>Figure S2</p>
<p>Figure S6</p>
<p>Figure S5</p>
<p>Figure S3</p>
<p>Figure S3</p>
<p>Figure S5</p>
<p>Figure S7</p>
<p>Figure S1</p>
<p>Figure S2</p>
<p>Figure S4</p>
<p>Figure S7</p>
<p>Figure S1</p>
<div>Abstract<p>Innovative strategies for enhancing efficacy and overcoming drug resistance in hematologic cancers, such as using antibody–drug conjugates (ADC), have shifted the paradigm of conventional care by delivering promising outcomes cancer therapies with a significant reduction risk relapse. Transferrin receptor (TfR1), cluster differentiation 71 (CD71), is known to be overexpressed malignant cells considered potent antitumor target. Therefore, we developed an anti-CD71...
<p>Figure S4</p>
<p>Figure S6</p>